More importantly, validation of the SSO‐QPOP‐identified combination of targeting CHK1 and BRD4 in our clinically relevant HCC‐PDXO models demonstrates the strong synergy and clinical actionability of the combination when HCC‐PDXOs are stratified based on their levels of MYC deregulation. This evidence concerns the gene BRD4 and hepatocellular carcinoma.